Thelen P, Strauss A, Stettner M, Kaulfuss S, Ringert R-H, Loertzer H
Urologische Universitätsklinik, Georg-August-Universität Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Deutschland.
Urologe A. 2010 Sep;49(9):1124, 1126-8, 1130. doi: 10.1007/s00120-010-2370-0.
In advanced prostate cancer, albeit castration resistant, an active androgen receptor is still pivotal for growth and cell survival. Recent therapies involving more effective antiandrogens such as MDV3100 proved to be successful. Furthermore, blocking de novo intracrine androgen synthesis, e.g. with abiraterone acetate, provides additional benefit. Besides these antiandrogen measures, compounds which enable the reconstitution of the oestrogen receptor beta as a tumour suppressor restrain aberrant androgen receptor signalling.
在晚期前列腺癌中，尽管存在去势抵抗，但活性雄激素受体对于肿瘤生长和细胞存活仍然至关重要。最近涉及更有效抗雄激素药物（如MDV3100）的治疗已被证明是成功的。此外，阻断从头内分泌雄激素合成，例如使用醋酸阿比特龙，可带来额外益处。除了这些抗雄激素措施外，能够重建作为肿瘤抑制因子的雌激素受体β的化合物可抑制异常的雄激素受体信号传导。
